West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, recently announced the Company's Board of Directors has elected Robert Friel as its newest member. With the addition of Mr. Friel, West's Board of Directors increases in size to 11 directors.

Mr. Friel, age 64, recently retired as Chairman and Chief Executive Officer of PerkinElmer, Inc., a role he served in for more than 10 years. During his 20-year career at PerkinElmer, a global business dedicated to serving the diagnostics, life sciences, food and applied markets, Mr. Friel held roles of increasing responsibility that included Chief Operating Officer, President of the Life and Analytical Sciences Division and Chief Financial Officer. Prior to joining PerkinElmer, Mr. Friel served in several finance-focused senior management positions with AlliedSignal, Inc., now Honeywell International. Mr. Friel sits on the Board of Directors of New York Life Insurance Company, NuVasive, Inc. and Xylem, Inc. He has prior board experience with CareFusion, Inc., Fairchild Semiconductor, Inc. and Millennium Pharmaceuticals, Inc. Mr. Friel holds a Master of Science degree in taxation from Fairleigh Dickinson University and a Bachelor of Arts degree in economics from Lafayette College.

"We welcome Robert Friel to West's Board of Directors," said Patrick J. Zenner, Chair of the Board of Directors, West. "Rob's extensive experience serving as both the Chairman and CEO of a global business focused on improving human health is well-aligned with West's mission and with the pharmaceutical and medical device customers our Company serves. With his significant board and industry experience, we know Rob will be a valuable addition to West's Board of Directors and look forward to working with him."